Thick as thieves

Thick as thieves

As we noted just the other day 2017 is shaping up as one of the wackier years for diabetes devices. Already we know that Johnson and Johnson (NYSE: JNJ) is divesting themselves of their franchise. Tandem (NASDAQ: TNDM) is on life support desperately seeking a buyer or at minimum additional capital. Roche says they are committed to diabetes yet at the same time has been shopping their unit. Abbott (NYSE: ABT) continues to bet the ranch on the Libre but few experts believe the product as it is structured today will be approved for patient use here in the US . . .

This content is restricted to subscribers. Please subscribe.

Already have an account? Please login.